FDA panel votes against Pfizer’s tanezumab for osteoarthritis pain
A joint FDA advisory committee has rejected a risk mitigation proposal for Pfizer and Eli Lilly’s osteoarthritis (OA) drug tanezumab,…
Pfizer
-
-
Pfizer reports data from tafamidis’ rare heart disease trial
A new phase III clinical trial has demonstrated that Pfizer’s tafamidis drug can lower the risk of death in patients…
-
BioNTech signs $425m flu vaccine deal with Pfizer
German biopharmaceutical company BioNTech has signed a research and development (R&D) agreement with Pfizer for the development of mRNA-based vaccines…
-
Pfizer’s Xeljanz secures marketing authorisation in Europe
Pfizer has received approval from the European Commission (EC) to market Xeljanz (tofacitinib citrate) for the treatment of adults suffering…
-
Pfizer to build $465m injectable medicines facility in US
Pfizer has revealed plans to invest $465m for the construction of an advanced sterile injectable pharmaceutical manufacturing plant at Portage…
-
Pfizer to split into three businesses
Pfizer has revealed plans to reorganise into the company into three different businesses, namely Innovative Medicines, Established Medicines, and Consumer…
